<SEC-DOCUMENT>0001193125-23-262456.txt : 20231025
<SEC-HEADER>0001193125-23-262456.hdr.sgml : 20231025
<ACCEPTANCE-DATETIME>20231025101536
ACCESSION NUMBER:		0001193125-23-262456
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20231025
DATE AS OF CHANGE:		20231025

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollomics Inc.
		CENTRAL INDEX KEY:			0001944885
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-272552
		FILM NUMBER:		231344352

	BUSINESS ADDRESS:	
		STREET 1:		989 EAST HILLSDALE BLVD.
		STREET 2:		STE 220
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		1-650-209-4055

	MAIL ADDRESS:	
		STREET 1:		989 EAST HILLSDALE BLVD.
		STREET 2:		STE 220
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d465146d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-272552</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT NO. 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to prospectus dated
September&nbsp;29, 2023) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APOLLOMICS INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Primary Offering of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11,043,102 Class&nbsp;A Ordinary Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Secondary Offering of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>88,538,394 Class&nbsp;A Ordinary Shares </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>619,400 Warrants to Purchase Class&nbsp;A Ordinary Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement amends and supplements the prospectus dated September&nbsp;29, 2023 (the &#147;Prospectus&#148;) which forms a part
of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1,</FONT> as amended and supplemented (Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-272552).</FONT> This prospectus supplement is being filed to update
and supplement the information included in the Prospectus with the press release (the &#147;Press Release&#148;) issued by Apollomics Inc. (the &#147;Company&#148;) on October&nbsp;23, 2023. The Press Release is attached to this prospectus
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not
be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the
information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
Class&nbsp;A ordinary shares, par value $0.0001 per share (&#147;Class&nbsp;A Ordinary Shares&#148;), and warrants to purchase Class&nbsp;A Ordinary Shares (&#147;Warrants&#148;) are traded on The Nasdaq Capital Market (&#147;Nasdaq&#148;) under the
symbols &#147;APLM&#148; and &#147;APLMW,&#148; respectively. The last reported sale price of the Ordinary Shares and the Warrants on October&nbsp;24, 2023 was $0.94 per share and $0.03 per warrant, respectively, as reported on Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>You should read the Prospectus and any prospectus supplement or amendment carefully before you invest in our securities. Investing in the
Company&#146;s securities involves risks. See &#147;</B><B><I>Risk Factors</I></B><B>&#148; beginning on page 25 of the Prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the SEC nor any state securities commission has approved or disapproved of the securities to be issued under the Prospectus or
passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is October&nbsp;25, 2023. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g465146g1025043850481.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g465146g1025043850607.jpg" ALT="LOGO">
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Apollomics Announces Efficacy of Vebreltinib in NSCLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Patients with MetEx14 Skipping Mutation Achieving an </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overall Response Rate (ORR) of 75% </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOSTER
CITY, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) &#151; <U>Apollomics Inc.</U> (Nasdaq: <U>APLM</U>) (the &#147;Company&#148;), today announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at the European
Society of Medical Oncology Congress (ESMO) 2023, being held in Madrid, Spain from October <FONT STYLE="white-space:nowrap">20-24,</FONT> 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The
clinical results demonstrate the potential of vebreltinib as a new treatment for patients with cancers driven by MET alterations, particularly in <FONT STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer (NSCLC) with MetEx14 skipping
mutation,&#148; said Guo-Liang Yu, Ph.D., <FONT STYLE="white-space:nowrap">co-founder,</FONT> Chairman and Chief Executive Officer of Apollomics. &#147;We are also pleased to see that vebreltinib is making progress in clinical programs for patients
with various MET alterations.&#148;<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Phase 2 KUNPENG clinical trial conducted by Apollomics&#146; China partner, Avistone Biotechnology
Ltd. (Beijing Pearl Biotechnology Ltd.), vebreltinib showed efficacy in patients with locally advanced or metastatic NSCLC harboring <FONT STYLE="white-space:nowrap">Exon-14</FONT> skipping mutations, with an ORR of 75%. Among other notable findings
in the KUNPENG study, ORR and disease control rate (DCR) were 100% in patients with brain metastases (n=5) and ORR was 66.7% in patients with liver metastases (n=6). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preliminary efficacy and safety data from the Phase 2 KUNPENG clinical trial (NCT04258033) is presented in poster 1378P. The poster or abstract are available
on the Apollomics website: <U>https://ir.apollomicsinc.com/news-events/presentations</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The data from NSCLC patients with MetEx14 skipping mutation
showed the following efficacy results: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Of the 52 patients, 39 achieved complete or partial response, an ORR of 75% (95% CI, <FONT
STYLE="white-space:nowrap">61.1-86.0),</FONT> median duration of response (DOR) of 15.9 months (95% CI, <FONT STYLE="white-space:nowrap">9.2-17.8),</FONT> a high disease control rate (DCR) of 96.2% (95% CI, 86.8 to 99.5). and a notably rapid onset
of response with a median time to response of 1 month (95% CI, 1, 2.8). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In the 35 <FONT STYLE="white-space:nowrap">treatment-na&iuml;ve</FONT> patients, ORR was 77.1% (95% CI, <FONT
STYLE="white-space:nowrap">59.9-89.6),</FONT> with median DOR of 16.5 months (95% CI, <FONT STYLE="white-space:nowrap">9.2-NE).</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In the 17 patients who received prior systemic treatment, ORR was 70.6% (95% CI,
<FONT STYLE="white-space:nowrap">44.0-89.7),</FONT> with median DOR of 15.3 months (95% CI, <FONT STYLE="white-space:nowrap">3.7-17.8).</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About vebreltinib <FONT STYLE="white-space:nowrap">(APL-101)</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vebreltinib is a potent, small molecule, orally bioavailable and highly selective <FONT STYLE="white-space:nowrap">c-MET</FONT> inhibitor. It works by
inhibiting the aberrant activation of the <FONT STYLE="white-space:nowrap">HGF/c-MET</FONT> axis, a key pathway involved in tumor growth, proliferation, and the development of resistance to certain targeted therapies such as osimertinib. Vebreltinib
is under clinical development for treatment of solid tumors with Met alterations by Apollomics globally and by Avistone Biotechnology in China. Vebreltinib NDA for <FONT STYLE="white-space:nowrap">exon-14</FONT> skipping NSCLC is under review by
NMPA in China. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g465146g1025043850481.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g465146g1025043850607.jpg" ALT="LOGO">
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <U>Apollomics Inc.</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to
be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the
clinical stage of development. Apollomics&#146; lead programs include vebreltinib <FONT STYLE="white-space:nowrap">(APL-101),</FONT> a potent, selective <FONT STYLE="white-space:nowrap">c-Met</FONT> inhibitor for the treatment of <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer and other advanced tumors with <FONT STYLE="white-space:nowrap">c-Met</FONT> alterations, and uproleselan <FONT STYLE="white-space:nowrap">(APL-106),</FONT> a specific <FONT
STYLE="white-space:nowrap">E-Selectin</FONT> antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Statement Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release includes statements that constitute &#147;forward-looking statements&#148; within the meaning of the federal securities laws, including
Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). All statements, other than statements of present or
historical fact included in this press release, regarding clinical trials and results, as well as the Company&#146;s strategy, business plans and objectives of management are forward-looking statements. In addition, Apollomics cautions you that the
forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including: (i)&nbsp;the impact of any current or new government regulations in the United States and China affecting
Apollomics&#146; operations and the continued listing of Apollomics&#146; securities; (ii)&nbsp;the inability to achieve successful clinical results or to obtain licensing of third-party intellectual property rights for future discovery and
development of Apollomics&#146; oncology projects; (iii) the failure to commercialize product candidates and achieve market acceptance of such product candidates; (iv)&nbsp;the failure to protect Apollomics&#146; intellectual property;
(v)&nbsp;breaches in data security; and other risks included in the Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> filed with the SEC and other SEC filings that are available publicly on the SEC&#146;s website at www.sec.gov.
Apollomics undertakes no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements,
except to the extent required by applicable laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTACTS</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Relations</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter Vozzo</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ICR Westwicke</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Peter.Vozzo@westwicke.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-443-213-0505</FONT></FONT></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Relations</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sean Leous </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ICR Westwicke </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Sean.Leous@westwicke.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-646-866-4012</FONT></FONT></FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g465146g1025043850481.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g465146g1025043850481.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ )P# 2(  A$! Q$!_\0
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M-]_:&G:'=!=JSPF7;Z9"UU'P\7'A&$XZR.?UKE_B6D5O/I=I"H5(8"%4=AD
M?RKL? T9C\'V.?X@[?FQKYF%GC)M?UL?<U[QR>DGO?\ S.AHKEM;\=Z;HVI_
MV<(+J]NE&9([5 VP=>>?2FV/Q TG4;;4KBWBN3'81>;(60 L/;GK]:]3ZO5Y
M>;ET/F?K-+FY>;4ZNBN%_P"%IZ.0D@LM0-N2 \_E#:A/8\UO:OXMTG1M*@U"
M:8RQW(S;K$,M+QGC_P"O0\/5BTG'<(XFC)-J2T-RBN:T'QMINNWK6*Q7%I>
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<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g465146g1025043850607.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g465146g1025043850607.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  G *4# 2(  A$! Q$!_\0
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)10 E%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
